Neonmind’s NEO-002 artificial psilocybin applicant will be examined as a very low-dose treatment to control and suppress individual urge for food. The company has secured pharmaceutical grade synthetic psilocybin from Psygen and anticipates initiating a Phase I/II proof-of-principle review for NEO-001 during the in the vicinity of long run. https://elizabethr368zbd3.blogrenanda.com/profile